Department of Pharmacology, University of Oxford, Oxford, UK.
Department of Experimental Psychology, University of Oxford, Oxford, UK.
J Psychopharmacol. 2022 Jul;36(7):794-805. doi: 10.1177/02698811221093032. Epub 2022 May 23.
Abrupt cessation of therapy with a selective serotonin reuptake inhibitor (SSRI) is associated with a discontinuation syndrome, typified by numerous disabling symptoms, including anxiety. Surprisingly, little is known of the behavioural effect of SSRI discontinuation in animals.
Here, the effect of SSRI discontinuation on anxiety-like behaviour was systematically investigated in mice.
Experiments were based on a three-arm experimental design comprising saline, continued SSRI and discontinued SSRI. Mice were assessed 2 days after SSRI discontinuation over a 5-day period using the elevated plus maze (EPM) and other anxiety tests.
An exploratory experiment found cessation of paroxetine (12 days) was associated with decreased open-arm exploration and reduced total distance travelled, in male but not female mice. Follow-up studies confirmed a discontinuation effect on the EPM in male mice after paroxetine (12 days) and also citalopram (12 days). Mice receiving continued paroxetine (but not citalopram) also showed decreased open-arm exploration but this was dissociable from the effects of discontinuation. The discontinuation response to paroxetine did not strengthen after 28 days of treatment but was absent after 7 days of treatment. A discontinuation response was not discernible in other anxiety and fear-learning tests applied 3-5 days after treatment cessation. Finally, discontinuation effects on the EPM were typically associated with decreased locomotion on the test. However, separate locomotor testing implicated anxiety-provoked behavioural inhibition rather than a general reduction in motor activity.
Overall, this study provides evidence for a short-lasting behavioural discontinuation response to cessation of SSRI treatment in mice.
选择性 5-羟色胺再摄取抑制剂(SSRIs)的治疗突然中断与停药综合征有关,其特征是出现许多使人丧失能力的症状,包括焦虑。令人惊讶的是,人们对动物中 SSRIs 停药的行为影响知之甚少。
本研究系统地研究了 SSRIs 停药对小鼠焦虑样行为的影响。
实验基于一个三臂实验设计,包括盐水、持续 SSRI 和停药 SSRI。在 SSRI 停药后 2 天,通过高架十字迷宫(EPM)和其他焦虑测试,在 5 天内评估小鼠。
一项探索性实验发现,帕罗西汀(12 天)停药与雄性而非雌性小鼠的开放臂探索减少和总行进距离减少有关。后续研究证实,帕罗西汀(12 天)和西酞普兰(12 天)停药后,雄性小鼠在 EPM 上也存在停药效应。接受持续帕罗西汀(但不是西酞普兰)治疗的小鼠也表现出开放臂探索减少,但这与停药的影响不同。帕罗西汀治疗 28 天后,停药反应没有增强,但治疗 7 天后,停药反应消失。在停药后 3-5 天进行的其他焦虑和恐惧学习测试中,未发现停药反应。最后,EPM 上的停药效应通常与测试时的运动减少有关。然而,单独的运动测试表明,这是焦虑引起的行为抑制,而不是一般的运动活动减少。
总的来说,这项研究为小鼠 SSRI 治疗突然停药后出现短暂的行为停药反应提供了证据。